White Blood Cell Growth Factors
Key Points
Key Points
Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen.
Dose-dense regimens that require CSFs should be used only within an appropriately designed clinical trial or if supported by convincing efficacy data.
Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.
Diagnosis
...gnosis...
...atient Risk Factors for Febrile Neutro...
...e 2. Patient Risk Factors for Poor...
Treatment for Adult Patients
Treatment for Adult Patie...
...ary prophylaxis with a CSF starting with th...
...rophylaxis with a CSF is recommended for pati...
...Fs should not be routinely used for patients...
...hould not be routinely used as adjunctive treatme...
...r breast cancer and lymphoma] ( EB , H , B ,...
...helial cancer] ( EB , H , H , M...
...Fs may be used alone, after chemotherap...
...be administered after autologous st...
...administered after allogeneic stem-cell...
...rophylactic CSFs for patients with diffus...
...filgrastim, filgrastim, tbo-filgrastim, and filgra...
...mendations for the management of patients exp...
Treatment for Pediatric Patients
...for Pediatric Patients...
...SFs in pediatric patients will almost always...
...or pediatric indications in which dose-intense c...
...should not be used in pediatric patients with...
Table 3. Dosing and Administration of CSFs
...ing and Administration of CSFsHaving trouble viewi...